🚀 VC round data is live in beta, check it out!
Hanall Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hanall Biopharma and similar public comparables like Chongqing Genrix, Bora Pharmaceuticals, Alembic Pharmaceuticals, RAPT Therapeutics and more.
Hanall Biopharma Overview
About Hanall Biopharma
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
Founded
1973
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Hanall Biopharma Financials
Hanall Biopharma reported last 12-month revenue of $107M and EBITDA of $5M.
In the same LTM period, Hanall Biopharma generated $57M in gross profit, $5M in EBITDA, and $278K in net income.
Revenue (LTM)
Hanall Biopharma P&L
In the most recent fiscal year, Hanall Biopharma reported revenue of $106M and EBITDA of $3M.
Hanall Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $107M | XXX | $106M | XXX | XXX | XXX |
| Gross Profit | $57M | XXX | $55M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $5M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 1% | XXX | XXX | XXX |
| Net Profit | $278K | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | 0% | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hanall Biopharma Stock Performance
Hanall Biopharma has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Hanall Biopharma's stock price is $32.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -1.0% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHanall Biopharma Valuation Multiples
Hanall Biopharma trades at 15.6x EV/Revenue multiple, and 367.1x EV/EBITDA.
EV / Revenue (LTM)
Hanall Biopharma Financial Valuation Multiples
As of April 18, 2026, Hanall Biopharma has market cap of $2B and EV of $2B.
Equity research analysts estimate Hanall Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hanall Biopharma has a P/E ratio of 6011.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 15.6x | XXX | 15.8x | XXX | XXX | XXX |
| EV/EBITDA | 367.1x | XXX | 484.9x | XXX | XXX | XXX |
| EV/EBIT | 867.3x | XXX | 2239.3x | XXX | XXX | XXX |
| EV/Gross Profit | 29.4x | XXX | 30.6x | XXX | XXX | XXX |
| P/E | 6011.2x | XXX | (739.8x) | XXX | XXX | XXX |
| EV/FCF | (2968.1x) | XXX | (1324.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hanall Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hanall Biopharma Margins & Growth Rates
Hanall Biopharma's revenue in the last 12 month grew by 6%.
Hanall Biopharma's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hanall Biopharma's rule of X is 19% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hanall Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | 108% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 19% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hanall Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Alembic Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| RAPT Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohaven | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hanall Biopharma M&A Activity
Hanall Biopharma acquired XXX companies to date.
Last acquisition by Hanall Biopharma was on XXXXXXXX, XXXXX. Hanall Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hanall Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHanall Biopharma Investment Activity
Hanall Biopharma invested in XXX companies to date.
Hanall Biopharma made its latest investment on XXXXXXXX, XXXXX. Hanall Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hanall Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hanall Biopharma
| When was Hanall Biopharma founded? | Hanall Biopharma was founded in 1973. |
| Where is Hanall Biopharma headquartered? | Hanall Biopharma is headquartered in South Korea. |
| Who is the CEO of Hanall Biopharma? | Hanall Biopharma's CEO is Seung-Guk Park. |
| Is Hanall Biopharma publicly listed? | Yes, Hanall Biopharma is a public company listed on Korea Exchange. |
| What is the stock symbol of Hanall Biopharma? | Hanall Biopharma trades under 009420 ticker. |
| When did Hanall Biopharma go public? | Hanall Biopharma went public in 1989. |
| Who are competitors of Hanall Biopharma? | Hanall Biopharma main competitors are Chongqing Genrix, Bora Pharmaceuticals, Alembic Pharmaceuticals, RAPT Therapeutics. |
| What is the current market cap of Hanall Biopharma? | Hanall Biopharma's current market cap is $2B. |
| What is the current revenue of Hanall Biopharma? | Hanall Biopharma's last 12 months revenue is $107M. |
| What is the current revenue growth of Hanall Biopharma? | Hanall Biopharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Hanall Biopharma? | Current revenue multiple of Hanall Biopharma is 15.6x. |
| Is Hanall Biopharma profitable? | Yes, Hanall Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hanall Biopharma? | Hanall Biopharma's last 12 months EBITDA is $5M. |
| What is Hanall Biopharma's EBITDA margin? | Hanall Biopharma's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Hanall Biopharma? | Current EBITDA multiple of Hanall Biopharma is 367.1x. |
| What is the current FCF of Hanall Biopharma? | Hanall Biopharma's last 12 months FCF is ($564K). |
| What is Hanall Biopharma's FCF margin? | Hanall Biopharma's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Hanall Biopharma? | Current FCF multiple of Hanall Biopharma is (2968.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.